drugset / Trial / NCT00773812

Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders

NCT00773812

Phase 1 Completed 20 enrolled Ohio State University Autism Speaks · collab
RandomizedFactorialQuadruple-blindTreatment

Summary

The purpose of this study is to examine the safety and efficacy of mecamylamine for the core symptoms of autism.

Timeline

Start
2007-07
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Mecamylamine Small molecule 5 mg

Indications